According to TipRanks.com, Kalia is a 5-star analyst with an average return of 9.6% and a 54.0% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.
Currently, the analyst consensus on Dexcom is a Moderate Buy with an average price target of $150.42.
Based on Dexcom’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $46.6 million. In comparison, last year the company had a GAAP net loss of $2 million.
Based on the recent corporate insider activity of 103 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DXCM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, Dexcom studio and Mobile apps.